JUBLPHARMA

US subsidiary, Jubilant Cadista Pharmaceuticals, passed a FDA Post-marketing Adverse Drug Experience inspection with zero observations on September 19, 2025. The company reports 9.2% year-on-year revenue growth to ₹1,901 crore in Q1 FY26, driven by segments like CRDMO, sterile injectables, and generics, with EBITDA growing 14% to ₹302 crore.